DBV Technologies (DBVT)vsRevolution Medicines Inc (RVMD)
DBVT
DBV Technologies
$16.59
-5.63%
HEALTHCARE · Cap: $981.61M
RVMD
Revolution Medicines Inc
$155.69
+3.11%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
DBV Technologies generates 673% more annual revenue ($5.74M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 24/100 (F).
DBVT
Avoid23
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+72.5%
Fair Value
$82.17
Current Price
$16.59
$65.58 discount
Intrinsic value data unavailable for RVMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -80.7% — below average capital efficiency
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : DBVT
The strongest argument for DBVT centers on Debt/Equity. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : DBVT
The primary concerns for DBVT are EPS Growth, Market Cap, Profit Margin.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
DBVT is growing revenue faster at 12.5% — sustainability is the question.
DBVT generates stronger free cash flow (-50M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RVMD scores higher overall (24/100 vs 23/100). DBVT offers better value entry with a 72.5% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DBV Technologies
HEALTHCARE · BIOTECHNOLOGY · USA
DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, France.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?